References
References
- Ekins , S and Wrighton , SA . 2001 . Application of in silico approaches to predict drug–drug interactions . J. Pharmacol. Toxicol. Methods , 45 : 65 – 69 .
- Hardman JG Goodman AG Limbird LE 2001 Goodman and Gilman's the Pharmacological Basis of Therapeutics, McGraw-Hill New York 1924 2023
- Guengerich , FP . 1991 . Oxidation of toxic and carcinogenic chemicals by human cytochrome-P-450 enzymes . Chem. Res. Toxicol. , 4 : 391 – 407 .
- Bertz , RJ and Granneman , GR . 1997 . Use of in vitro in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions . J. Clin. Pharmacokinetics , 32 : 210 – 258 .
- Anzenbacher , P and Anzenbacherova , E . 2001 . Cytochromes P450 and metabolism of xenobiotics . Cell. Mol. Life Sci. , 58 : 737 – 747 .
- Danielson , PB . 2002 . The Cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans . Curr. Drug Metab. , 3 : 561 – 597 .
- Lewis , DFV . 2000 . On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics . Biochem. Pharmacol. , 60 : 293 – 306 .
- Lewis , DFV and Dickins , M . 2002 . Substrate SARs in human P450s . Drug Disc. Today , 7 : 918 – 925 .
- Fuhr , U . 1996 . Systematic screening for pharmacokinetic interactions during drug development . Int. J. Clin. Pharmacol. Ther. , 34 : 139 – 151 .
- Michalets EL et al. 1998 Update: clinical significant cytochrome P-450 drug interactions Pharmacotherapy 18 84 112
- Tredger , JM and Stoll , S . 2002 . Cytochromes P450–Their impact on drug treatment . Hosp. Pharmacist , 9 : 167 – 173 .
- Raevsky OA 1997 Hydrogen-bond strength estimation by means of the HYBOT program package van de Waterbeemd H Testa B Folkers G Computer-Assisted Lead Finding and Optimisation, Wiley-VCH Basel 367 378
- Hardman JG Goodman AG Limbird LE 1996 Goodman and Gilman's the Pharmacological Basis of Therapeutics, McGraw-Hill New York 1710 1792
- Jones , BC , Hawksworth , G , Horne , VA , Newlands , A , Morsman , J , Tute , MS and Smith , DA . 1996 . Putative active site template model for cytochrome P450 CYP2C9 . Drug Metab. Dispos. , 24 : 260 – 266 .
- Mancy , A , Broto , P , Dijols , S , Dansette , PM and Mansuy , D . 1995 . The substrate binding site of human liver CYP450 CYP2C9: an approach using designed tienilic acid derivatives and molecular modelling . Biochemistry , 34 : 10365 – 10375 .
- De Groot , MJ and Ekins , S . 2002 . Pharmacophore modelling of cytochrome P450 . Adv. Drug Delivery Rev. , 54 : 367 – 383 .
- Shen , M , Xiao , Y , Golbraikh , A , Gombar , VK and Tropsha , A . 2003 . Development and validation of k-nearest neighbor QSPR models of metabolic stability of drug candidates . J. Med. Chem. , 46 : 3013 – 3020 .
- Smith , DA , Ackland , BJ and Jones , BC . 1997 . Properties of cytochrome P450 isoenzymes and their substrates. Part 2: properties of cytochrome P450 substrates . Drug Disc. Today , 2 : 479 – 486 .
- Susnow , R and Dixon , SL . 2003 . Use of robust classification techniques for the prediction of human cytochrome P4502D6 inhibition . J. Chem. Inf. Comput. Sci. , 43 : 1308 – 1315 .